Apex Labs*

APEX Ticker Reserved**

* Apex Labs Ltd. conducts business as Apex Labs.
** Apex Labs Ltd. has reserved the ticker symbol “APEX” with the NEO Exchange. The company currently holds the NEO Exchange private company ticker symbol of “APEXL”.

Spring
2022

Why APEX?

1

Unique Value Proposition

- CTA approved by Health Canada for phase 2a clinical trial
- APEX-002 GMP API product sourced from Psygen and formulated for clinical and human use
- Supported Canada's first approved psilocybin SAP application
- Subsection 56(1) exemptions filed with Health Canada through TheraPsil
- Access to over 3,000 Veteran patients for clinical and medical programs

2

Under Valued

- Current value allows for growth upon proposed 2022 public listing and undervalued compared to peers
- Large private shareholder base of over 350 investors
- Asset light model with low overhead
- CAD$12mm pre-money valuation

APEX is a socially focused pharmaceutical company.

APEX's clinical development program is focused on Veterans – a population disproportionately affected by mental health conditions. The Company's lead clinical candidate is a low-dose synthetic psilocybin product for the treatment of Post-Traumatic Stress Disorder (PTSD) and treatment resistant depression.

APEX's strategy is to develop drug products including Active Pharmaceutical Ingredients (API) produced by chemical synthesis, and also drug products with botanically sourced API, differentiating **APEX** by diversifying **APEX's** options for development and commercialization of drug products.

Mission

To bring psychedelic drugs to market through commercialization of drug products and, where possible, through medical access, in both Canada and the USA.

Vision

Global Good Manufacturing Practices (GMP) supply chain secured with a Licensed Dealer to create synthetic APIs, cultivate fruiting bodies and preparing botanical extracts.

Strategy

APEX aims to be at the forefront of both psilocybin drug development and medical access by working directly with Veterans. **APEX** is aligned with TheraPsil, a non-profit advocacy group focused on psilocybin medical access.

Directors & Officers

Tyler Powell

Chief Executive Officer & Director

Capital markets entrepreneur with 15 years of experience in the financial sector leading numerous IPO's & RTO's on North American & German Exchanges

Arron Victory

Chief Strategy Officer & Director

Ambassador for Wounded Warriors Canada & Advisor to the Chronic Pain Centre of Excellence & Heroic Hearts Project with patient & operational expertise

Dr. Orion Lekos

Chief Science Officer & Director

Led global clinical trials while being instrumental in the development & design of the extractions and formulations for a top three global cannabis company

Dr. Peter Tomlinson

Chief Medical Officer

Prominent industry leader specializing in clinical trials & pharmaceutical commercialization partnering with leading companies such as Tilray, Aegera, Purgenesis, Ultragenyx, Sharp & Taro

Sam Isaac

Chief Financial Officer

Brings 15 years of international capital markets experience, having worked with publicly traded companies and raised over $100 million in equity capital

Alex Winstead

Chief Cultivation Officer

Renowned mycologist, cultivator & founder/ CEO of Cascadia Mushrooms with over 16 years' experience in the gourmet & medicinal mushroom industry

Dr. Enrique Carrazana

Director

Harvard-trained Neurologist with a career spanning over 25 years in drug development and the pharmaceutical industry.

Tom McGaugh

Director

Provides nearly two decades of financial accounting excellence & experience supporting start-ups, small businesses & publicly traded companies across the globe

Jim Pakulis

Director

Vast executive corporate experience as CEO & Director of numerous successful public & private companies across North America raising millions in conjunction

Strategic Advisors

Raashid Naik	Pharmacist and Senior Director at Shopper’s Drug Mart
Dr. Paul Smith	Patient Recruitment
Dr. Emmanouil Rampakakis	Clinical Trial Protocols Specialist
Dana Nohynek	Clinical Development and Regulatory Affairs
Dr. Kevin Lutz	Veteran and PTSD Clinician
Dr. David Wood	Intellectual Property and Regulatory Attorney
Dr. Bal Kang	Drug Development
Bob Cross	Capital Markets and Corporate Structure
Susan Chapelle	Operations
Denis Silva	Corporate Securities Attorney
Martin Cronin	Veteran Advocate

Canadian Landscape

Mental Health Synopsis

$51B

Estimated annual economic burden of mental illness in Canada

20%

Number of Canadians who suffer from addiction in any given year

4th

Canada's worldwide rank per capita in anti-depressant drug usage

50%

Number of Canadians who will be affected by mental health issues by the age of 40

PTSD

9th

Leading cause of deaths nationwide attributed to suicide with an average of 11 per day

76%

Of Canadians have reported experiencing a traumatic event reshaping their mental health

9%

Of PTSD patients not receptive to current traditional treatments

8%

Of Canadians suffer from PTSD at least once in their lifespan

* See Footnotes on page 17

Drug Development - 3 Phase Approach

1 Research & Development

Dr. Lekos oversees Research and Development (R&D) alongside Dr. Kang to lead exploration of Intellectual Property (IP) formulations for **APEX**'s synthetic drug product APEX-002 used in upcoming clinical trials and medical access. Dr. Lekos and Alex Winstead will head further R&D projects on genetics, extraction and formulation of botanical psilocybin products for clinical trials.

2 Clinical Trial Planning

Dr. Tomlinson, Dr. Wood and Dana Nohynek will oversee regulatory efforts and manage the Clinical Trial Application (CTA) and Investigational New Drug Application (IND) for all clinical trials with help from the Clinical Research Organization (CRO) JSS Medical Research will support the clinical trials as a private CRO by auditing target clinical sites and assisting with monitoring and data management.

3 Clinical Trial Execution

Dr. Rampakakis and Dr. Tomlinson combined clinical and GMP expertise will allow **APEX** to develop, protect and commercialize drug products manufactured under GMP standards. A minimum of two different drug products are planned for clinical trials - one with psilocybin as an API and another with a botanical extract of psilocybin. Other tryptamines and beta carbolines are also being evaluated.

Critical Path

1 CTA Approval

APEX has an approved CTA with Health Canada for a phase 2a randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability and efficacy of psilocybin in Veterans with Post-traumatic stress disorder using drug product APEX-002.

2 Product Sourcing

APEX has sourced API from Dealer Licenced (DL) Psygen's 17,000 square foot Calgary, AB facility under GMP-compliance with the ability to produce large-scale synthesis of psychedelic compounds. Psygen's DL site is built to Compliance with Level 9 of the Security Directive*, allowing ample storage of controlled substances to secure North American supply.

3 Launch

APEX will launch multiple clinical trials with Veterans in Canada and the US. **APEX** has assembled a clinical team that has successfully conducted both phase 2 and phase 3 clinical trials with psychedelic compounds.

* Directive on Physical Security Requirements for Controlled Substances and Drugs Containing Cannabis

Clinical Timeline



Apex Labs

* Clinical Trial Application
** Quality Overall Summary

Psygen – Drug Source

APEX has sourced both GMP and non-GMP psilocybin from Psygen to further its R&D and clinical path to market. Psygen and APEX have worked together arranging all supporting Chemistry, Manufacturing, and Controls (CMC) data, Quality Overall Summary (QOS) and Investigator Brochure (IB) for the CTA application.

About Psygen:
Psygen is a dedicated psychedelics GMP manufacturer. Psygen has harnessed more than 50 years of combined experience synthesizing psychedelics to provide a catalogue of APIs for clinicians, researchers, and drug developers

About Psygen Team:
Psygen's goal is to become the world's most trusted source for pharmaceutical grade psychedelic APIs. The team at Psygen is inspired by a duty to provide these medicines and to ensure their transformative potential is better understood and accessible to the industry.

Psygen teams holds sector-leading capabilities in psychedelic medicinal chemistry, manufacturing, formulation, and management. Psygen's directors and advisors are experts in pharmacology, regulatory compliance, law and finance.



Patient Recruitment

APEX is working with JSS Research to further identify how Veterans can benefit from medical access and psychedelic-supported psychotherapy based on clinical evidence.

Veterans

APEX's Veteran-focused research team will be studying PTSD, treatment resistant depression, traumatic brain injury and chronic pain in the Canadian and American Veteran communities. We believe in a whole-person approach to recovery for Veterans who suffer from chronic service-related conditions with patient support from over 3,000 Veteran patients.

Access Channels



Exemptions & SAP

Currently Health Canada allows psilocybin access to patients through two avenues outside of clinical trials, subsection 56(1) exemptions and the recently revised Special Access Program (SAP). With Therapsil's assistance, **APEX** has filed subsection 56(1) exemptions for Veterans to access psilocybin for therapeutic benefit where other treatments have failed. **APEX** believes that the SAP will provide an additional path to medical access in specific cases.

Special Access Program

On March 21st, 2022, Dr. Valorie Masuda MD received authorization under the Special Access Program (SAP) to treat six patients experiencing end-of-life distress with psilocybin and psychotherapy. GMP synthetic psilocybin was donated by Psygen Labs Inc., and **Apex Labs Ltd**. provided access to its psilocybin investigators' brochure, in support of the SAP application. This is the first known case of psilocybin being accessed through Canada's SAP since the Food and Drug Regulations were amended on January 5th, 2022, to allow access to psilocybin and other restricted drugs through the SAP. The six patients were treated in early April of 2022 by Roots to Thrive, co-led by Dr. Masuda.

This is the first legal medical access to psilocybin outside of a clinical trial in Canadian history.



Intellectual Property

Genetic Registration & Rights

APEX has filed provisional US patent Application, which relates to extraction methods for tryptamines via Cooley LLP.

APEX intellectual property development plan prioritizes patent protection of development genetics, compositions, formulations and target indications for drug products. We combine these aspects together to bolster and diversify our patent claims, particularly in formulations prepared from extracts of botanical biomass and synthetic forms.

There is an incredible opportunity for developing and securing intellectual property rights in the psilocybin, psilocin and psychedelic space. APEX is working in conjunction with our intellectual property counsel at Cooley LLP, DLA Piper (USA) LLP and R-Group Legal, identifying the assets that can be protected and effectively captured to capitalize on.

Revenue Model

1

Exemptions

APEX has filed and is actively pursuing further subsection 56(1) exemptions for Veteran medical access through TheraPsil.

2

SAP

Now with broadened SAP regulations, **APEX** will engage its Veteran patient base for access to APEX-002 product.

3

Sales

APEX has the ability to sell controlled substances to other Dealer's Licences and federal Drug Enforcement Administration (DEA) licence holders for profit.

4

DIN

Achieve Drug Identification Number (DIN) by developing a psilocybin drug product, a botanical extract and/or synthetics through established regulatory processes.

Capital Structure

Basic Structure	24.0mm
Options (@ $0.25)	6.5mm
Warrants (@ $0.20)	6.5mm
Half Warrants (@ $0.50)	6.8mm
Fully Diluted	40.4mm
Price of raise	$0.50
Units (Half Warrant $0.75)	8.0mm
Basic Proforma Market Cap	$16.0mm
FD Proforma Market Cap	$24.2mm
FD Proforma Cash	$10.6mm
Current Cash Position	$800k

Use of Proceeds

Clinical Program Development	$2.0mm
Drug Development & Manufacturing	$500k
IPO Related Expenses	$250k
Marketing	$500k
Working Capital and Fees	$750k

* Numbers may be subject to change.

Partners & Associates

Innomar Strategies
Health Canada liaison and literature research

Psygen
17,000 square foot state-of-the-art lab facility with active Dealer's

R-Group Law
Law firm handling **APEX's** Canadian Regulatory and IP

Cooley LLC
Top US Patent Firm

DLA Piper (Canada) LLP
Leading global legal firm managing the corporate, securities and go public path for **APEX**

Changemark Research
Site Operations & Regulatory

AlthoTech
GMP certification expert consulting outfit

Cascadia Mushrooms
Pacific Northwest leader in organic fungi cultivation

TheraPsil
Canada's leading non-profit advocating for nationwide psychedelic medical access

JSS Medical Research
Clinical Research Organization (CRO) handling clinical trials and protocols

Footnotes

Global Stats

www.ncbi.nlm.nih.gov/pmc/articles/PMC6394282
www.who.int/news-room/fact-sheets/detail/depression
www.who.int/substance_abuse/information-sheet/en
www.who.int/whr/2001/media_centre/press_release/en

Canadian Stats

www.cpa.ca/sections/traumaticstress/simplefacts
www.health.gov.on.ca/en/public/publications/mental/depression.aspx https://www.addictioncenter.com/addiction/addiction-in-canada
www.canada.ca/en/public-health/services/publications/diseases-conditions/mood-anxiety-disorders-canada

Disclaimer

NOTICE TO INVESTORS

This presentation (the "Presentation") is being issued by Apex Labs Ltd. (the "Company") for information purposes, confidential and proprietary materials, and may contain certain material information about the Company, including important disclosures and risk factors applicable to the Company and the proposed private placement offering (the "Offering") of securities of the Company (the "Securities") the proposed as further described in this Presentation. The purpose of this Presentation is to provide information regarding the Company, including with respect to the Company's business, operations, and the psychedelics industry generally. This Presentation has not been prepared to assist any reader in making a decision whether to invest in the Company and the contents of this Presentation have not been approved or disapproved by any securities commission or regulatory authority in Canada, the United States or any other jurisdiction. In making an investment decision, prospective investors must rely on their own examination of the Company and the terms of the Offering as further detailed in the term sheet accompanying this Presentation (the "Term Sheet"), as applicable, including the merits and risks involved in purchasing the Securities. Prospective investors should not construe the contents of this presentation as legal, tax, investment or accounting advice by the Company or any of its directors, officers, shareholders, agents, employees or advisors. This Presentation does not take into account the particular investment objectives or financial circumstances of any prospective investor. Each prospective investor who reviews this Presentation must make its own independent assessment of the Company and the Securities after making such investigations and each prospective investor is strongly urged to consult with its own advisors with respect to legal, tax, regulatory, financial and accounting consequences, including the merits and risks involved, of any investment in the Company and its Securities.

By purchasing securities offered under this Presentation, each investor is deemed to acknowledge that its express wish is that all documents evidencing or relating in any way to the sale of the Securities be drafted in the English language only. En souscrivant des valeurs mobilières en vertu de la présente notice d'offre, chaque souscripteur est réputé reconnaître avoir exigé que tous les documents faisant foi de ou relatifs à la vente des valeurs mobilières soient rédigés uniquement en anglais.

This Presentation contains highly confidential information regarding the investments, strategy and organization of the Company and is being delivered to you in reliance on your agreement in the following sentences. Your acceptance of this document constitutes, and shall be deemed to constitute, your agreement to (i) keep confidential all the information contained in this Presentation, as well as any information derived by you from the information contained in this Presentation (collectively, "Confidential Information") and not disclose any such Confidential Information to any other person, (ii) not use any of the Confidential Information for any purpose other than to evaluate the purchase of Securities of the Company, (iii) not copy this document without the Company's prior consent, and (iv) promptly return this document and any copies hereof to the Company upon the Company's request.

In making an investment decision, prospective investors should rely on their own examination of the Company and the terms of the Private Placement, including the merits and risks involved. Prospective investors should not construe the contents of this Presentation as legal, tax, investment or accounting advice by the Company or any of its directors, officers, shareholders, agents, employees or advisors. This Presentation does not take into account the particular investment objectives or financial circumstances of any specific party who may receive it. Each party who reviews this Presentation must make its own independent assessment of the Company after making such investigations and each prospective investor is strongly urged to consult with its own advisors with respect to legal, tax, regulatory, financial and accounting consequences, including the merits and the risks involved, of any investment in the Company. In particular, any estimates, projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumption and each recipient should satisfy itself in relation to such matters. Investment in the Company is suitable only for sophisticated investors and requires the financial ability and willingness to accept the high risks and lack of liquidity that are characteristic of an investment in "seed" or "risk" capital for an entity which is in a speculative stage of development.

Certain information contained herein includes market and industry data that has been obtained from or is based upon estimates derived from third party sources, including industry publications, reports and websites. Third party sources may state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance or guarantee as to the accuracy or completeness of included data. Although the data is believed to be reliable, neither the Company nor its agents have independently verified the accuracy, currency, reliability or completeness of any of the information from third party sources referred to in this Presentation or ascertained from the underlying economic assumptions relied upon by such sources. The Company and its agents hereby disclaim any responsibility or liability whatsoever in respect of any third party sources of market and industry data or information.

This Presentation has not been independently verified and the information contained within may be subject to updating, revision, verification and further amendment. Except as otherwise provided for herein, neither the Company, nor its directors, officers, shareholders, agents, employees or advisors give, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, currency, reliability or completeness of the information or opinions in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers and liability therefore is expressly disclaimed for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

Except as may be required by applicable law, in furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies or omissions.

CONFIDENTIALITY NOTICE

Information contained in this Presentation is the property of the Company and it is made available strictly for the purposes referred to above in the "Notice to Investors" (the "Permitted Purpose"). By accepting this Presentation, each recipient agrees that it will not copy, reproduce, disclose or distribute to others this Presentation or the information contained herein, in whole or in part, at any time, without the prior written consent of the Company. The recipient further agrees that it and each of its directors, officers, employees and representatives shall use this Presentation only for the Permitted Purpose and for no other purpose. The recipient acknowledges and agrees that the information contained herein: constitutes the Company's proprietary information; is valuable proprietary and confidential information of the Company developed at considerable cost and effort; and that such information is the sole and exclusive property of the Company. The recipient further acknowledges and agrees that it shall not obtain any rights or licenses in, ownership of or entitlements to any of such proprietary information or any underlying intellectual property rights.

NOTICE REGARDING FORWARD LOOKING INFORMATION

Certain information included in this Presentation constitutes forward looking information under applicable securities legislation that involve substantial known and unknown risks and uncertainties. This information relates to future events or future performance of the Company. Forward-looking information are statements that are not historical facts and are often, but not always, identified using words or phrases such as "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "predict", "seek", "propose", "expect", "potential", "continue", and other similar expressions. In particular, but without limiting the foregoing, this Presentation contains forward-looking information pertaining to, among other things: the terms of the transactions proposed and certain other transactions described in this Presentation (the "Transactions"); expectations regarding the timing of steps to complete the Transactions; future growth plans; the capitalization and debt levels of the Company; the intention of the Company to seek out and target acquisitions; the effects of the Transactions; the Company's growth and business strategies; targeted customer base and resulting revenues in the near to mid term; the Company's ability to develop drug products from both synthetic and botanically sources compounds; the successful completion of the forthcoming clinical trials; the Company's ability to market and showcase the benefits of extracted botanically-sourced tryptamines, beta-carbonlines and other compounds, and also of single-molecule synthetic psilocin; Dr. Lekos heading further R&D projects using controlled substances to be added as A/QPIC to Innovate's dealer's license (once issued); the Company's relationship with JSS Medical Research in its support of the clinical trials as a private CRO; the two additional drug products planned for clinical trials; and the Company's relationship with JSS Research to further identify how Veterans, First Responders and First Nations can benefit from psychedelic supported psychotherapy from an evidence-based perspective.By its nature, forward-looking information involves known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated. Such forward-looking information is provided for the purpose of providing information about management's current expectations and plans relating to the future. Investors are cautioned that reliance on such information may not be appropriate for other purposes, such as making investment decisions. These factors and risks include, without limitation: risks that all necessary regulatory and third party approvals will not be forthcoming; risks that parties to the Transactions will not be satisfied with their respective due diligence procedures; risks that the parties will not be able to identify appropriate risks associated with drug development involving extracts from naturally occurring psychedelic alkaloids; exchange rate fluctuations; changes in legislation affecting psilocybin and other psychoactive based compounds and additives; uncertainties resulting from potential delays or changes in plans with respect to the acquisition and development of future facilities; risks involving the Company's dependency on its strategic partners to develop and commercialize its product; the reliance on key scientific advisors to led the research and development effort and bring the development of the Company's product to market; the reliance on key advisors with assisting the Company navigate the applicable legal and regulatory framework; and the discussions with multiple laboratories that have successfully synthesized psychedelics fails to materialized With respect to forward looking information in this Presentation, the Company has made assumptions, regarding, among other things: shareholder and regulatory approvals for the Transactions and the receipt of those approvals; assumptions regarding the success of the production of synthetic psychedilec compounds, assumptions regarding the success of extraction and isolation of natural psychedelic compounds; the expected market size of the global psychedelics industry; the availability of capital; current legislation; and general economic conditions. Although the Company believes that the expectations reflected in such forward looking information are reasonable, such statements are not guarantees of future performance and actual results may differ materially from those in statements of forward-looking information. Undue reliance should not be placed on forward looking information because the Company can give no assurance that such expectations will prove to be correct and such statements are based on the beliefs, estimates and opinions of the Company's management on the date such statements are made. Many factors could cause the Company's actual results, performance or achievements to vary from those described herein. Should one or more of these risks or uncertainties materialize, or should assumptions underlying forward looking information prove incorrect, actual results may differ materially from those described in this Presentation as intended, planned, anticipated, believed, estimated or expected.

The forward-looking information included in this Presentation is expressly qualified in its entirety by this cautionary statement. The Company cautions that the foregoing lists of assumptions, risks and uncertainties is not exhaustive. The forward-looking information contained in this Presentation is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws.

Any financial outlook or future oriented financial information in this document, as defined by applicable securities legislation, has been approved by management of the Company. Such financial outlook or future oriented financial information is provided for the purpose of providing information about management's current expectations and management's plans relating to the future of the Company. Readers are cautioned that reliance on such information may not be appropriate for other purposes.

Market data and industry forecasts contained in this Presentation have been obtained from industry publications, various publicly available sources and subscription-based reports as well as from management's good faith estimates, which are derived from management's knowledge of the industry and independent sources that management believes to be reliable. Industry publications, publicly-available sources and subscription-based reports generally state that the information contained therein has been obtained from sources believed to be reliable. We have not independently verified any of the information from such third-party sources nor have we ascertained the validity or accuracy of the underlying economic assumptions relied upon therein. The Company hereby disclaims any responsibility or liability whatsoever in respect of any third party sources of market and industry data or information.

PURCHASER'S STATUTORY RIGHTS OF RECISSION

Securities legislation in certain of the provinces and territories of Canada provides purchasers with a statutory right of action for damages or rescission in cases where an offering memorandum or any amendment thereto contains an untrue statement of a material fact or omits to state a material fact that is required to be stated or is necessary to make any statement contained therein not misleading in light of the circumstances in which it was made (a "misrepresentation"). These rights, or notice with respect thereto, must be exercised or delivered, as the case may be, by purchasers within the time limits prescribed and are subject to the defences and limitations contained under the applicable securities legislation. The subscription agreement for any investment in the securities of the Company will include summaries of these rescission rights and prospective purchasers should refer to the securities legislation applicable in their province or territory along with the regulations, rules and policy statements thereunder for the complete text of these provisions or should consult with their legal advisor.

Thank You

Apex Labs

Chris Brown
info@apexlabs.com
1-888-331-3244